- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02628795
Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement (TWEAK)
3 juillet 2021 mis à jour par: Marcas M. Bamman, PhD, University of Alabama at Birmingham
This single-blind, randomized, controlled trial is designed to test the effect of an intensive, 16 week exercise rehabilitation program (progressive resistance training + functional mobility training) vs. usual care on restoration of muscle mass and mobility after total hip (THA) or knee (TKA) arthroplasty in men and women with end-stage osteoarthritis.
The molecular basis underlying the trial is the presence of significant muscle inflammation susceptibility in many of these individuals, and the expectation that the more intensive intervention will overcome this inflammatory burden to facilitate recovery.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
While elective total hip (THA) and knee (TKA) arthroplasty relieve pain and improve mobility function for thousands with end-stage osteoarthritis (OA), up to 35% endure persistent muscle atrophy and mobility limitations for several years that impact life quality, increase morbidity, and burden the healthcare system.
Given that THA/TKA volumes are increasing exponentially with >1.1 million in the US annually, refractory mobility impairment is a major public health problem.
Together, the available data raise two important knowledge gaps in THA/TKA rehabilitation: (i) poorly understood factors that limit responsiveness of a large number of patients to current usual care; and (ii) the absence of rehabilitation programs proven to overcome these limitations.
The proposed project is designed to fill these gaps.
The investigators' fundamental tenet is that restoration of mobility function following THA/TKA requires: (i) regeneration of surgically damaged muscle; and (ii) regrowth of muscles that have atrophied over years of OA and limited usage.
The investigators suggest a major cause of muscle regeneration impairment in some individuals is what the investigators identified as muscle inflammation susceptibility (MuIS) - hyperactive inflammatory signaling in muscle of MuIS(+) individuals despite no systemic inflammation - which also manifests in isolated primary satellite cells and inhibits myogenesis in vitro, indicative of a true cellular phenotype beyond the niche.
The investigators' preliminary findings in THA/TKA patients strongly suggest the tumor necrosis factor-like weak inducer of apoptosis (TWEAK) signaling pathway may be central to MuIS and impaired THA/TKA recovery, as high perioperative muscle TWEAK signaling in the ipsilateral thigh was the most sensitive indicator of impaired muscle protein synthesis and failed strength recovery after 8 wk of usual care.
Progressive resistance exercise training (PRT) is a putative anabolic intervention that the investigators find consistently increases muscle mass to meet healthy standards in atrophied and mobility-impaired adults, by activating muscle protein synthesis and the myogenic activity of muscle satellite cells.
Together, these findings raise the central hypothesis that PRT plus adjunctive functional mobility training (PRT+FM) after THA/TKA will more effectively restore muscle mass and mobility function to healthy standards than usual care and, because MuIS(+) are predicted to suffer failed muscle recovery and persistent dismobility under usual care, the impact of PRT+FM will be greatest in MuIS(+).
The investigators will thoroughly test this hypothesis in a randomized controlled trial of 88 THA/TKA patients with the following aims.
Aim 1: To determine the effects of 16 wk of PRT+FM vs. usual care after elective THA/TKA on muscle mass, performance, and mobility function.
Aim 2: To determine whether MuIS status modifies the effects of PRT+FM or usual care after THA/TKA.
Cellular and molecular mechanisms of muscle mass regulation will be studied in detail.
Aim 3. To determine the long-term impact of 16 wk PRT+FM by re-assessing outcomes at 6 mo and 1 y.
The investigators fully expect the novel findings to lead a paradigm shift in THA/TKA rehabilitation that will have a profound impact on a growing segment of the population.
Type d'étude
Interventionnel
Inscription (Réel)
80
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35205
- UAB Center for Exercise Medicine
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
40 ans à 80 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
Between the ages 40 and 80 y.
- Scheduled to undergo elective total hip or knee replacement specifically for the surgical indication of end-stage osteoarthritis.
- First-time hip or knee replacement.
- Capable of providing informed consent (cognitively intact if consenting to surgery).
Exclusion Criteria:
Any surgical indication other than first-time total joint replacement specifically for end-stage osteoarthritis.
- Bilateral knee/ hip replacement
- History of alcoholism or liver disease.
- Any history of hypo- or hyper-coagulation disorders including subjects taking Coumadin.
- Any individual with end-stage disease and/or a life expectancy less than one year.
- Pregnancy.
- Lactating Women.
- Neurological, musculoskeletal, or other disorder that would preclude them from completing the exercise training intervention and all performance tests.
- Uncontrolled hypertension, unstable or exercise-induced angina pectoris or myocardial ischemia, congestive heart failure.
- Uncontrolled diabetes mellitus.
- Any other condition or events considered exclusionary by the PIs and/or physician Co-Is.
- Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
- Phenylketonuria (phenylalanine tracer for metabolic studies).
- Currently receiving androgen (e.g., testosterone) or anabolic (e.g., growth hormone (GH), insulin-like growth factor-I (IGF-I)) therapy.
- Body mass index ≥ 35.
- History of lower body progressive resistance training within the past year.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PRT + FM
Progressive resistance training + functional mobility training 3 d/wk x 16 wk
|
Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
Post-surgical usual care activities including any prescribed physical therapy
|
|
Comparateur actif: Usual Care
Post-surgical usual care including physical therapy
|
Post-surgical usual care activities including any prescribed physical therapy
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in unilateral (surgical) thigh muscle mass (unit of measure = grams)
Délai: Pre-surgery to 16 weeks post-surgery
|
Primary muscle mass outcome of Aim 1
|
Pre-surgery to 16 weeks post-surgery
|
|
Change in unilateral (surgical) knee extension power (unit of measure = watts)
Délai: Pre-surgery to 16 weeks post-surgery
|
Primary functional outcome of Aim 1
|
Pre-surgery to 16 weeks post-surgery
|
|
Change in short physical performance battery (SPPB) (unit of measure = score)
Délai: From 16 weeks post-surgery to 26 and 52 weeks post-surgery
|
Primary outcome of Aim 3
|
From 16 weeks post-surgery to 26 and 52 weeks post-surgery
|
|
Muscle inflammation susceptibility (MuIS) status (unit of measure = relative value)
Délai: At the time of surgery
|
Primary outcome of Aim 2: Muscle inflammation susceptibility (MuIS) defined by TWEAK receptor gene expression
|
At the time of surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change in muscle fiber size (unit of measure = micrometers squared)
Délai: From the time of surgery to 16 weeks post-surgery
|
From the time of surgery to 16 weeks post-surgery
|
|
Change in unilateral (surgical) knee extension isometric strength (unit of measure = Newton-meters)
Délai: Pre-surgery to 16 weeks post-surgery
|
Pre-surgery to 16 weeks post-surgery
|
|
Change in maximum 10-meter gait speed (unit of measure = meters per second)
Délai: Pre-surgery to 16 weeks post-surgery
|
Pre-surgery to 16 weeks post-surgery
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in free-living physical activity (unit of measure = steps per day)
Délai: Pre-surgery to 8, 16, 26, and 52 weeks post-surgery
|
Via wearable technology (i.e.
step counter)
|
Pre-surgery to 8, 16, 26, and 52 weeks post-surgery
|
|
Change in self-reported health status (unit of measure = score)
Délai: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Via Short Form-36v2 Health Survey (SF-36v2)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in cellular and molecular markers (unit of measure = arbitrary units)
Délai: From the time of surgery to 16 weeks post-surgery
|
Experiments using muscle tissue and primary muscle satellite cells collected from surgical and contralateral limbs.
|
From the time of surgery to 16 weeks post-surgery
|
|
Change in fatigue (unit of measure = score)
Délai: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Via Patient Reported Outcomes Measurement Information System (PROMIS)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in pain (unit of measure = score)
Délai: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Via Patient Reported Outcomes Measurement Information System (PROMIS)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in depression (unit of measure = score)
Délai: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Beck Depression Inventory (BDI II)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in fatigue severity (unit of measure = score)
Délai: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Fatigue Severity Scale (FSS)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Marcas M Bamman, PhD, University of Alabama at Birmingham
- Chercheur principal: S Louis Bridges, MD, PhD, University of Alabama at Birmingham
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 octobre 2015
Achèvement primaire (Réel)
1 septembre 2020
Achèvement de l'étude (Réel)
28 février 2021
Dates d'inscription aux études
Première soumission
5 août 2015
Première soumission répondant aux critères de contrôle qualité
10 décembre 2015
Première publication (Estimation)
11 décembre 2015
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
7 juillet 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
3 juillet 2021
Dernière vérification
1 juillet 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- R01HD084124 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
INDÉCIS
Description du régime IPD
Data might be provided on written request in aggregate form.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .